	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	356	438	630	797	893	767	913	1,000	1,134	1,376	1,491	1,852	2,177	2,623	2,951
Cost of Operating Revenue	241	274	389	482	565	512	583	560	618	655	793	973	1,169	1,313	1,376
Gross Profit	115	165	241	315	328	255	330	440	516	721	698	879	1,009	1,310	1,575
Gross Margin	32.3	37.6	38.3	39.5	36.8	33.3	36.1	44.0	45.5	52.4	46.8	47.5	46.3	49.9	53.4
Total Operating Expenses	381	388	532	637	789	764	861	891	969	1,073	1,277	1,554	1,789	2,159	2,446
Operating Profit	-26	50	98	160	104	3	52	109	166	303	214	299	388	464	505
Operating Margin	-7.2	11.5	15.6	20.1	11.7	0.4	5.7	10.9	14.6	22.1	14.4	16.1	17.8	17.7	17.1
Financing Income/(Expense) - Net	-55	-10	-12	-4	3	12	-2	-5	-9	-7	18	43	31	42	-24
Profit before Taxes	-175	44	86	156	107	15	50	104	157	302	248	338	424	504	561
Income Taxes	1	-5	13	44	24	4	14	24	36	64	61	72	109	121	140
Profit after Tax	-179	46	72	109	79	9	33	76	117	236	185	266	314	381	418
PAT Margin	-50.3	10.5	11.4	13.7	8.8	1.2	3.6	7.6	10.3	17.1	12.4	14.4	14.4	14.5	14.2
EPS - Basic - ex Extraordinary Items	-4.86	1.19	1.87	2.67	1.92	0.22	0.80	1.87	2.86	5.76	4.51	6.41	6.92	8.40	9.22
EPS - Diluted - ex Extraordinary Items	-4.86	1.19	1.87	2.67	1.92	0.22	0.80	1.87	2.86	5.76	4.51	6.41	6.92	8.40	9.22
EBIT	-26	50	98	160	104	3	52	109	166	303	214	299	388	464	505
EBITDA	-2	66	114	176	132	33	78	132	192	340	259	350	463	547	603
EBITDA Margin	-0.6	15.0	18.1	22.1	14.8	4.3	8.6	13.2	17.0	24.7	17.4	18.9	21.2	20.9	20.4

Balance Sheet

Abridged

Understanding Balance Sheet

Marksans Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	216	244	343	509	440	484	451	531	594	902	1,201	1,675	1,862	2,204	2,723
Long-Term Investments	-	-	-	-	10	1	1	1	3	3	3	3	3	0	4
Property Plant & Equipment - Net	74	74	72	102	164	165	186	198	230	254	342	387	681	895	941
Total Non-Current Assets	169	157	147	167	280	268	282	272	309	326	439	515	818	1,036	1,138
Total Assets	385	401	490	676	720	752	732	804	903	1,228	1,640	2,190	2,681	3,240	3,861
Total Current Liabilities	519	297	319	286	251	296	235	233	229	298	356	341	390	477	527
Long Term Debt	15	8	20	-	13	11	10	10	13	14	41	66	190	263	270
Total Non-Current Liabilities	28	10	22	1	16	16	17	18	25	24	61	84	205	273	281
Total Liabilities	548	308	341	288	267	312	252	251	254	323	417	425	595	750	808
Total Shareholders' Equity	-168	86	142	380	445	433	471	542	636	886	1,202	1,745	2,065	2,467	3,023
Minority Interest	6	7	7	8	8	6	10	10	13	19	21	20	21	22	30
Total Equity	-162	93	149	388	453	440	480	553	649	905	1,223	1,765	2,086	2,489	3,053
Total Liabilities & Equity	385	401	490	676	720	752	732	804	903	1,228	1,640	2,190	2,681	3,240	3,861

Cash Flow

Abridged

Understanding Cash Flow Statement

Marksans Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	-65.69	54.21	81.17	128.82	117.53	35.89	76.65	96.31	164.72	324.94	210.50	353.23	382.29	478.85	544.04
Working Capital - Increase/(Decrease)	-8.06	-26.11	-26.01	20.27	-84.16	-24.10	-36.67	-78.48	36.57	-153.18	-110.70	-111.47	-126.19	-240.77	-62.46
Net CF from Operating Activities	-73.74	28.10	55.16	149.09	33.37	11.79	39.98	17.83	201.30	171.76	99.79	241.76	256.10	238.08	481.59
Capital Expenditures - Net	5.28	6.43	5.21	36.47	131.87	27.75	38.94	13.15	59.63	45.91	46.30	53.25	207.98	171.67	129.55
Net CF from Investing Activities	-5.28	-6.43	-5.21	-36.47	-131.87	-27.75	-38.92	-13.57	-59.63	-45.91	-89.15	-269.63	-171.71	-82.81	-274.51
Dividends Paid - Cash - Total	0.27	4.68	10.42	6.97	17.96	14.53	2.46	4.44	29.50	4.09	10.58	10.17	22.66	27.19	36.25
Stock - Issuance/(Retirement) - Net	-	4.48	-	130.24	-	-1.50	-1.00	-	-5.00	-	91.16	229.54	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-11.23	-235.12	-8.46	-99.87	-33.50	21.85	17.07	-6.68	-46.35	-3.21	3.16	-15.48	-40.90	-35.57	-31.89
Net Cash Flow from Financing Activities	70.49	-28.19	-18.89	25.69	-51.46	5.82	13.61	-11.12	-81.40	-7.30	83.73	203.90	-63.55	-62.76	-68.14
Free Cash Flow to Equity	-90.25	-213.44	41.49	12.76	-132.00	5.89	18.11	-2.00	95.32	122.65	56.66	173.03	7.22	30.84	320.15
Free Operating CF net dividend	-79.29	17.00	39.53	105.65	-116.47	-30.49	-1.42	0.24	112.17	121.25	42.88	177.96	24.61	37.97	314.81
Free Operating CF	-79.02	21.68	49.96	112.63	-98.51	-15.96	1.04	4.68	141.67	125.34	53.46	188.13	47.26	65.16	351.06

Business Segment Analysis

FY End:

Mar 25

Marksans Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing and marketing of Pharmaceutical (100.0%)₹ 172.92 Cr

Revenue / Sales

Manufacturing and marketing of Pharmaceutical (100.0%)₹ 2,622.85 Cr

Assets

Manufacturing and marketing of Pharmaceutical (100.0%)₹ 3,239.63 Cr

Operating Income

Manufacturing and marketing of Pharmaceutical (100.0%)₹ 463.84 Cr

Regional Segment Analysis

FY End:

Mar 25

Marksans Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

US & North America (43.0%)₹ 1,236.56 CrEurope and UK (35.8%)₹ 1,029.82 CrAustralia & NZ (8.8%)₹ 252.81 CrAustralia & NZ (8.8%)₹ 252.81 CrRest of World (3.6%)₹ 103.66 Cr

Historical Segment Analysis

Track how Marksans Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacturing and marketing of Pharmaceutical	46	46	54	209	173

Frequently Asked Questions

What is the revenue of Marksans Pharma Ltd.?

The latest trailing twelve month revenue of Marksans Pharma Ltd. is ₹ 2,950.94 Cr, reflecting a 1-year growth of 12.51% and a 3-year CAGR of 16.80%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Marksans Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Marksans Pharma Ltd. is ₹ 417.90 Cr, with a 3-year earnings CAGR of 12.88%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Marksans Pharma Ltd.?

The trailing twelve month EBITDA of Marksans Pharma Ltd. is approximately ₹ 504.76 Cr (based on an operating margin of 17.10%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Marksans Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Marksans Pharma Ltd. is 9.22. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Marksans Pharma Ltd.?

The debt-to-equity ratio of Marksans Pharma Ltd. stands at 0.11. The interest coverage ratio is 20.92x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Marksans Pharma Ltd.?

The estimated book value per share of Marksans Pharma Ltd. is 66.71 (derived from a P/B ratio of 3.95 and market price of ₹ 263.45), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Marksans Pharma Ltd.?

The trailing twelve month operating cash flow of Marksans Pharma Ltd. is ₹ 481.59 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Marksans Pharma Ltd. report consolidated or standalone financials?

Marksans Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.